Harrow Health (NASDAQ:HROW) Research Coverage Started at B. Riley

B. Riley assumed coverage on shares of Harrow Health (NASDAQ:HROWGet Rating) in a research note released on Thursday, The Fly reports. The firm issued a buy rating and a $17.00 price objective on the stock.

Separately, TheStreet downgraded Harrow Health from a c- rating to a d+ rating in a research note on Thursday, May 19th.

Harrow Health Trading Up 0.4 %

NASDAQ:HROW opened at $9.08 on Thursday. The company has a quick ratio of 4.61, a current ratio of 5.01 and a debt-to-equity ratio of 13.36. Harrow Health has a 1-year low of $5.40 and a 1-year high of $12.99. The firm has a market capitalization of $245.80 million, a price-to-earnings ratio of -10.09 and a beta of 0.65. The stock has a fifty day simple moving average of $7.80 and a 200 day simple moving average of $7.22.

Harrow Health (NASDAQ:HROWGet Rating) last released its quarterly earnings results on Tuesday, August 9th. The company reported $0.01 earnings per share for the quarter. The business had revenue of $23.32 million during the quarter. Harrow Health had a positive return on equity of 17.50% and a negative net margin of 28.96%. Sell-side analysts forecast that Harrow Health will post -0.21 earnings per share for the current year.

Institutional Investors Weigh In On Harrow Health

Several hedge funds have recently bought and sold shares of the business. Bailard Inc. lifted its stake in Harrow Health by 9.9% in the 2nd quarter. Bailard Inc. now owns 16,837 shares of the company’s stock worth $123,000 after acquiring an additional 1,515 shares in the last quarter. Prelude Capital Management LLC raised its stake in shares of Harrow Health by 3.1% during the 2nd quarter. Prelude Capital Management LLC now owns 97,819 shares of the company’s stock worth $712,000 after purchasing an additional 2,908 shares in the last quarter. Millennium Management LLC raised its stake in shares of Harrow Health by 2.1% during the 2nd quarter. Millennium Management LLC now owns 202,396 shares of the company’s stock worth $1,473,000 after purchasing an additional 4,257 shares in the last quarter. State Street Corp raised its stake in shares of Harrow Health by 5.5% during the 1st quarter. State Street Corp now owns 86,813 shares of the company’s stock worth $592,000 after purchasing an additional 4,521 shares in the last quarter. Finally, First Trust Advisors LP raised its stake in shares of Harrow Health by 14.1% during the 4th quarter. First Trust Advisors LP now owns 39,277 shares of the company’s stock worth $339,000 after purchasing an additional 4,865 shares in the last quarter. 59.83% of the stock is owned by hedge funds and other institutional investors.

Harrow Health Company Profile

(Get Rating)

Harrow Health, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc, a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc, a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc, a commercial-stage pharmaceutical company that engages in developing and commercializing drug products.

See Also

The Fly logo

Receive News & Ratings for Harrow Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harrow Health and related companies with MarketBeat.com's FREE daily email newsletter.